Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

PRINCETON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced advancements for two members of its management team. Rene Belder, M.D., Vice President, Clinical and Regulatory Affairs, has been promoted to Senior Vice President, Clinical and Regulatory Affairs, and the role of S. David Kimball, Ph.D., Senior Vice President, Chemistry and Preclinical Chemical Development, has been expanded to include all of research, and his title has been changed to Senior Vice President, Discovery. The company also announced that David M. Floyd, Ph.D. is retiring effective March 31, 2008 from his position as Executive Vice President and Chief Scientific Officer. However, Dr. Floyd will rejoin Pharmacopeia's scientific advisory board and continue to consult for the company in the area of scientific direction and strategy.

"David Floyd has had an important impact on Pharmacopeia since arriving at the company more than three years ago. He has facilitated the successful transformation of Pharmacopeia into a clinical stage development company by helping to build our broad pipeline," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "While we are saddened to see him leave his day-to-day position, we are very pleased that he will once again be a member of our scientific advisory board and continue to provide his invaluable insight as a key consultant."

"I view my tenure as a member of the Pharmacopeia executive management team as very rewarding and look forward to remaining connected with the company through my SAB and consulting roles," stated Dr. Floyd. "We have made tremendous progress over the last thr
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... Form 10 with the U.S. Securities and Exchange ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form 10 ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... and NEW YORK, Sept. 17 ,Microbia, Inc. ... ), today announced,that they have entered into ... to,co-develop and co-market Microbia,s first-in-class compound linaclotide.,Linaclotide ... of,constipation-predominant irritable bowel syndrome (IBS-C), chronic,constipation (CC), ...
... Experience in Pulmonary and Infectious Disease ... ... a,clinical stage biopharmaceutical company focused on developing products to,overcome issues of ... Company,s Chief Medical Officer. Dr. Loutit,joins Mpex from InterMune, Inc. where ...
... Sept. 17 Kyphon Inc.,(Nasdaq: KYPH ... clearance from the,Federal Trade Commission (FTC) and ... Improvements Act of 1976 (as amended) with,respect ... assets,and associated intellectual property rights of Disc-O-Tech ...
Cached Biology Technology:Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 2Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 3Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 4Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration 5Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 2Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer 3Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech 2
(Date:8/19/2014)... parts of the world, leprosy and tuberculosis live ... of leprosy per year, with nearly all of ... available century-old vaccine Bacille Calmette-Guerin, or BCG, provides ... so a more potent vaccine is needed to ... a stronger weapon against both diseases., In a ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Despite ongoing public health efforts, E. coli ... sickness and death throughout the world. But the ... published today in the scientific journal Nature , researchers ... discovered a molecule,s previously unknown role in fighting off ...
... of North Carolina scientists have uncovered a new strategy ... and chronic obstructive pulmonary disorder better clear the thick ... to life-threatening infections. In a new report appearing online ... researchers show that the "SPLUNC1" protein and its derivative ...
... July 13, 2012, Shenzhen, China - An international team, ... Academy of Science, and BGI, the world,s largest genomics ... salt cress ( Thellungiella salsuginea ), a wild salt-tolerant ... tool for exploring mechanisms of adaptive evolution and sheds ...
Cached Biology News:La Jolla institute identifies critical cell in fighting E. coli infection 2La Jolla institute identifies critical cell in fighting E. coli infection 3New proteins to clear the airways in cystic fibrosis and COPD 2Salt cress genome yields new clues to salt tolerance 2
Green Standard is fluorescein....
Red Standard is sodium salt of resorufin....
Human Jagged 2 Biotinylated Affinity Purified PAb...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: